This suggests that it must be feasible to specifically interfere with either physiological or oncogenic ErbB2 signaling, to activate ErbB2 signaling in heart failure with no increased risk for cancer on the one hand, and to inhibit ErbB2 signaling in cancer with no increased risk for heart failure on the other hand. This evidence concerns the gene ERBB2 and heart failure.